Page last updated: 2024-12-07

ribavirin 5'-triphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ribavirin 5'-triphosphate: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ribavirin 5'-triphosphate : A 1-ribosyltriazole that is ribavirin in which the hydroxy group at the 5'-position is replaced by a triphosphate group. It is the active metabolite of the antiviral agent ribavirin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID122108
CHEMBL ID398463
CHEBI ID45578
MeSH IDM0114214

Synonyms (31)

Synonym
63142-71-2
[[(2r,3s,4r,5r)-5-(3-carbamoyl-1,2,4-triazol-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] phosphono hydrogen phosphate
ribavirin-5'-triphosphate
1-.beta.-d-ribofuranosyl-1,2,4-triazolo-3-carboxamide-5'-triphosphate
1h-1,2,4-triazole-3-carboxamide, 1-[5-o-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-b-d-ribofuranosyl]-
RTP ,
virazole 5'-triphosphate
ribavirin-tp
1h-1,2,4-triazole-3-carboxamide, 1-[5-o-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-beta-d-ribofuranosyl]-
ribavirin 5'-triphosphate
ribavirin triphosphate
1MN9
CHEMBL398463 ,
ribavirin 5'-triphosphate trisodium salt
[[(2r,3s,4r,5r)-5-(3-carbamoyl-1,2,4-triazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
bdbm50370554
unii-xa6l2vry2m
xa6l2vry2m ,
1h-1,2,4-triazole-3-carboxamide, 1-(5-o-(hydroxy((hydroxy(phosphonooxy)phosphinyl)oxy)phosphinyl)-beta-d-ribofuranosyl)-
ribavirin 5'-triphosphate sodium salt
W-203347
DTXSID10212490
1-{5-o-[(r)-hydroxy{[(r)-hydroxy(phosphonooxy)phosphoryl]oxy}phosphoryl]-beta-d-ribofuranosyl}-1h-1,2,4-triazole-3-carboxamide
Q27465138
1h-1,2,4-triazole-3-carboxamide, 1-(5-o-(hydroxy((hydroxy(phosphonooxy)phosphinyl)oxy)phosphinyl)-.beta.-d-ribofuranosyl)-
1-[5-o-(hydroxy{[hydroxy(phosphonooxy)phosphoryl]oxy}phosphoryl)-beta-d-ribofuranosyl]-1h-1,2,4-triazole-3-carboxamide
CHEBI:45578
1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide-5'-triphosphate
rbv-tp
63142-71-2 (non-salt)
1-d-ribofuranosyl-1,2,4-triazole-3-carboxamide-5'-triphosphate, sodium salt
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
human blood serum metaboliteAny metabolite (endogenous or exogenous) found in human blood serum samples.
drug metabolitenull
antiviral agentA substance that destroys or inhibits replication of viruses.
eukaryotic initiation factor 4F inhibitorAny compound that inihibits the mammalian protein, eukaryotic initiation factor 4F.
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitorA DNA polymerase inhibitor that interferes with the action of a RNA-directed RNA polymerase (EC 2.7.7.48).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
1-ribosyltriazoleA 1-glycosyltriazole in which the glycosyl residue is specified as ribosyl.
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
primary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with ammonia; formula RC(=O)NH2.
ribose triphosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyprotein IC50 (µMol)180.00000.70001.95673.8000AID240983
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, NDP kinaseDictyostelium discoideumKd24.000024.000024.000024.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID1541388Substrate activity at recombinant full-length human CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of GTP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541390Substrate activity at recombinant full-length chicken CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of GTP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541393Substrate activity at recombinant full-length chicken CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of ATP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID528360Binding affinity to Poliovirus RNA-dependent RNA polymerase2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
Synthesis of a 6-methyl-7-deaza analogue of adenosine that potently inhibits replication of polio and dengue viruses.
AID1541392Substrate activity at recombinant full-length mouse CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of ATP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID1541391Substrate activity at recombinant full-length human CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of ATP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID312070Incorporation of Poliovirus RNA dependent RNA polymerase into sym/sub-C primer2008Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1
Effects of introduction of hydrophobic group on ribavirin base on mutation induction and anti-RNA viral activity.
AID312075Ratio of kcat/Km of Poliovirus RNA dependent RNA polymerase incorporation into sym/sub-U primer2008Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1
Effects of introduction of hydrophobic group on ribavirin base on mutation induction and anti-RNA viral activity.
AID312072Ratio of kcat/Km of Poliovirus RNA dependent RNA polymerase incorporation into sym/sub-C primer relative to control2008Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1
Effects of introduction of hydrophobic group on ribavirin base on mutation induction and anti-RNA viral activity.
AID1541389Substrate activity at recombinant full-length mouse CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of GTP by HPLC-UV analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.
AID240983Inhibitory concentration against hepatitis C virus helicase2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
Control of hepatitis C: a medicinal chemistry perspective.
AID312071Incorporation of Poliovirus RNA dependent RNA polymerase into sym/sub-U primer2008Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1
Effects of introduction of hydrophobic group on ribavirin base on mutation induction and anti-RNA viral activity.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2003Molecular pharmacology, Mar, Volume: 63, Issue:3
Structural analysis of the activation of ribavirin analogs by NDP kinase: comparison with other ribavirin targets.
AID1811Experimentally measured binding affinity data derived from PDB2003Molecular pharmacology, Mar, Volume: 63, Issue:3
Structural analysis of the activation of ribavirin analogs by NDP kinase: comparison with other ribavirin targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (21.74)18.7374
1990's0 (0.00)18.2507
2000's10 (43.48)29.6817
2010's8 (34.78)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.17 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index5.35 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]